Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C

AIDS. 2013 Sep 24;27(15):2485-8. doi: 10.1097/QAD.0b013e328363b1f9.


NS3 protease inhibitors are set to improve sustained virological response rates in HIV-positive patients with hepatitis C. We measured the prevalence of natural resistance polymorphisms in 38 acutely infected treatment-naive patients using direct and deep sequencing. Twenty six percent of patients (10/38) had a majority variant resistance mutation (in order of frequency; Q80K - 16%, V36M - 5%, T54S - 3%, V55A - 3%, and D168A - 3%). Low-frequency mutations were detected in all samples. Further studies are required to determine threshold levels associated with treatment failure.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • HIV Infections / complications
  • Hepacivirus / genetics*
  • Hepatitis C / complications
  • Hepatitis C / genetics*
  • Humans
  • Polymorphism, Genetic / genetics*
  • RNA, Viral / genetics*


  • RNA, Viral